{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:50:06Z","timestamp":1790851806851,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004695","name":"Inyuvesi Yakwazulu-Natali","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["115969"],"award-info":[{"award-number":["115969"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jvacx.2023.100384","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T06:29:52Z","timestamp":1694068192000},"page":"100384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development"],"prefix":"10.1016","volume":"15","author":[{"given":"Nomfundo","family":"Ntombela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matome","family":"Matsiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sbahle","family":"Zuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhavna","family":"Hiralal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeann","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8278-2514","authenticated-orcid":false,"given":"Nobalanda","family":"Mokoena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thandeka","family":"Khoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jvacx.2023.100384_b0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/vms3.434","article-title":"Lumpy skin disease, an emerging transboundary viral disease: A review","volume":"7","author":"Namazi","year":"2021","journal-title":"Vet Med Sci"},{"issue":"7","key":"10.1016\/j.jvacx.2023.100384_b0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1865-1682.2008.01043.x","article-title":"Capripoxviruses: an emerging worldwide threat to sheep, goats and cattle","volume":"55","author":"Babiuk","year":"2008","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.jvacx.2023.100384_b0015","series-title":"Pseudo-urticaria of cattle","first-page":"20","author":"MacDonald","year":"1931"},{"issue":"3","key":"10.1016\/j.jvacx.2023.100384_b0020","first-page":"37","article-title":"Lumpy skin disease of cattle: a growing problem in Africa and the Near East","volume":"68","author":"Davies","year":"1991","journal-title":"World Anim Rev"},{"key":"10.1016\/j.jvacx.2023.100384_b0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fvets.2020.00256","article-title":"Protection of cattle elicited using a bivalent lumpy skin disease virus-vectored recombinant rift valley fever vaccine","author":"Wallace","year":"2020","journal-title":"Front Vet Sci"},{"issue":"22","key":"10.1016\/j.jvacx.2023.100384_b0030","first-page":"549","article-title":"Clinical and pathological studies of lumpy skin disease in Egypt","volume":"127","author":"Ali","year":"1990","journal-title":"Vet Rec"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100384_b0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4102\/jsava.v72i2.619","article-title":"Lumpy skin disease in southern Africa: a review of the disease and aspects of control","volume":"72","author":"Hunter","year":"2001","journal-title":"J S Afr Vet Assoc"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1865-1682.2011.01242.x","article-title":"lumpy skin disease: an emerging threat to Europe, the Middle East and Asia","volume":"59","author":"Tuppurainen","year":"2012","journal-title":"Transbound Emerg Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4102\/jsava.v85i1.1075","article-title":"Seroprevalence of Rift Valley fever and lumpy skin disease in African buffalo (Syncerus caffer) in the Kruger National Park and Hluhluwe-iMfolozi Park, South Africa","volume":"85","author":"Fagbo","year":"2014","journal-title":"J S Afr Vet Assoc"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100384_b0050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/tbed.12501","article-title":"Epidemiological and molecular studies on lumpy skin disease outbreaks in Turkey during 2014\u20132015","volume":"64","author":"\u015eevik","year":"2017","journal-title":"Transbound Emerg Dis"},{"issue":"10","key":"10.1016\/j.jvacx.2023.100384_b0055","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/vaccines9101136","article-title":"Vaccines and vaccination against lumpy skin disease","volume":"9","author":"Tuppurainen","year":"2021","journal-title":"Vaccines"},{"issue":"14","key":"10.1016\/j.jvacx.2023.100384_b0060","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/vr.135.14.330","article-title":"Adverse reactions in cattle to a capripox vaccine","volume":"135","author":"Yeruham","year":"1994","journal-title":"Vet Rec"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100384_b0065","doi-asserted-by":"crossref","DOI":"10.1111\/tbed.12257","article-title":"Adverse reactions to field vaccination against lumpy skin disease in Jordan","volume":"63","author":"Abutarbush","year":"2016","journal-title":"Transbound Emerg Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0070","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/tbed.12646","article-title":"Investigation on the incidence of adverse reactions, viraemia and haematological changes following field immunization of cattle using a live attenuated vaccine against lumpy skin disease","volume":"65","author":"Katsoulos","year":"2018","journal-title":"Transbound Emerg Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2023.100384_b0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/vaccines9060621","article-title":"Investigation of post vaccination reactions of two live attenuated vaccines against lumpy skin disease of cattle","volume":"9","author":"Bamouh","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.jvacx.2023.100384_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetmic.2020.108689","article-title":"Development and evaluation of an inactivated lumpy skin disease vaccine for cattle","volume":"245","author":"Hamdi","year":"2020","journal-title":"Vet Microbiol"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/vaccines9010004","article-title":"Development of a safe and highly efficient inactivated vaccine candidate against lumpy skin disease virus","volume":"9","author":"Wolff","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.jvacx.2023.100384_b0090","first-page":"100209","article-title":"Improved safety profile of inactivated Neethling strain of the lumpy skin disease vaccine","volume":"12","author":"Matsiela","year":"2022","journal-title":"Vaccine: X"},{"issue":"8","key":"10.1016\/j.jvacx.2023.100384_b0095","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3390\/biom11081072","article-title":"Platforms for production of protein-based vaccines: from classical to next-generation strategies","volume":"11","author":"Cid","year":"2021","journal-title":"Biomolecules"},{"issue":"31","key":"10.1016\/j.jvacx.2023.100384_b0100","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1016\/j.vaccine.2010.05.023","article-title":"Immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection","volume":"28","author":"Rudraraju","year":"2010","journal-title":"Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.jvacx.2023.100384_b0105","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.vaccine.2008.04.017","article-title":"Targrting vaccinia virus L1 protein to the cell surface enhances the production of nuetralizing antibodies","volume":"26","author":"Golden","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jvacx.2023.100384_b0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/v8060159","article-title":"Recombinant sheep pox virus proteins elicit neutralizing antibodies","volume":"8","author":"Chervyakova","year":"2016","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.jvacx.2023.100384_b0115","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1128\/jvi.64.10.4884-4892.1990","article-title":"Fusion of intra-and extracellular forms of vaccinia virus with the cell membrane","volume":"64","author":"Doms","year":"1990","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100384_b0120","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/JVI.72.2.1577-1585.1998","article-title":"A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate","volume":"72","author":"Chung","year":"1998","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0125","first-page":"47","article-title":"The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles","volume":"81","author":"Sanderson","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jvacx.2023.100384_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-2-91","article-title":"Importance of disulphide bonds for vaccinia virus L1R protein function","volume":"2","author":"Blouch","year":"2005","journal-title":"Virol J"},{"issue":"17","key":"10.1016\/j.jvacx.2023.100384_b0135","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1128\/JVI.00852-08","article-title":"Vaccinia virus L1 protein is required for cell entry and membrane fusion","volume":"82","author":"Bisht","year":"2008","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100384_b0140","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.virol.2008.12.019","article-title":"Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans","volume":"385","author":"Foo","year":"2009","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100384_b0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0042-6822(87)90481-8","article-title":"A 14K envelope protein of vaccinia virus with an important role in virus-host cell interactions is altered during virus persistence and determines the plaque size phenotype of the virus","volume":"159","author":"Dallo","year":"1987","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100384_b0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"21","key":"10.1016\/j.jvacx.2023.100384_b0155","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.jvacx.2023.100384_b0160","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1128\/JVI.00568-08","article-title":"Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge","volume":"82","author":"Fogg","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6750-12-95","article-title":"Use of anionic denaturing detergents to purify insoluble proteins after overexpression","volume":"12","author":"Schlager","year":"2012","journal-title":"BMC Biotech"},{"issue":"1\u20132","key":"10.1016\/j.jvacx.2023.100384_b0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jvacx.2023.100384_b0175","unstructured":"OIE, A., Manual of diagnostic tests and vaccines for terrestrial animals. Office international des epizooties, Paris, France, 2008: p. 1092-1106."},{"issue":"4","key":"10.1016\/j.jvacx.2023.100384_b0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1865-1682.2009.01067.x","article-title":"Detection of antibodies against capripoxviruses using an inactivated sheeppox virus ELISA","volume":"56","author":"Babiuk","year":"2009","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.jvacx.2023.100384_b0185","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00705-019-04170-8","article-title":"Prokaryotic expression, purification and evaluation of goatpox virus ORF117 protein as a diagnostic antigen in indirect ELISA to detect goatpox","volume":"164","author":"Dashprakash","year":"2019","journal-title":"Arch Virol"},{"issue":"3","key":"10.1016\/j.jvacx.2023.100384_b0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.51847\/Tb7RtCsagp","article-title":"Comparison of the Immunogenicity of GTPV A27R, GTPV L1R, and SPPV A33R Recombinant Proteins","volume":"10","author":"Hurisa","year":"2021","journal-title":"World J Environ Biosci"},{"key":"10.1016\/j.jvacx.2023.100384_b0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11259-020-09780-1","article-title":"A review: Lumpy skin disease and its emergence in India","volume":"44","author":"Gupta","year":"2020","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.jvacx.2023.100384_b0200","unstructured":"Roche X, et al., Introduction and spread of lumpy skin disease in South, East and Southeast Asia: Qualitative risk assessment and management. 2021: Food & Agriculture Org."},{"key":"10.1016\/j.jvacx.2023.100384_b0205","doi-asserted-by":"crossref","unstructured":"Authority EFS, et al., Lumpy skin disease epidemiological report IV: Data collection and analysis. Efsa J. 2020;18(2):p. e06010.","DOI":"10.2903\/j.efsa.2020.6010"},{"issue":"3","key":"10.1016\/j.jvacx.2023.100384_b0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"10.1016\/j.jvacx.2023.100384_b0215","doi-asserted-by":"crossref","unstructured":"Sarkar I, Garg R, van Drunen S, Littel-van den Hurk. Selection of adjuvants for vaccines targeting specific pathogens. Expert Rev Vacc. 2019;18(5):p. 505\u2013521.","DOI":"10.1080\/14760584.2019.1604231"},{"issue":"3","key":"10.1016\/j.jvacx.2023.100384_b0220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10295-011-1082-9","article-title":"Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements","volume":"39","author":"Huang","year":"2012","journal-title":"J Ind Microbiol Biotechnol"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0225","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1110\/ps.041022305","article-title":"Cloning and expression of multiple integral membrane proteins from Mycobacterium tuberculosis in Escherichia coli","volume":"14","author":"Korepanova","year":"2005","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100384_b0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.provac.2009.07.026","article-title":"Adjuvant formulation for veterinary vaccines: Montanide\u2122 Gel safety profile","volume":"1","author":"Parker","year":"2009","journal-title":"Procedia Vaccinol"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T07:12:07Z","timestamp":1719990727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136223001250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":46,"alternative-id":["S2590136223001250"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100384","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100384"}}